Keyphrases
Multiagent Chemotherapy
100%
Pancreatic Ductal Adenocarcinoma
100%
Cell-free DNA (cfDNA)
100%
Prolonged Response
100%
Variant Allele Frequency
66%
Progression-free Survival
50%
Carbohydrate Antigen 19-9 (CA19-9)
50%
Gemcitabine Plus Nab-paclitaxel
50%
KRAS Variant
50%
Overall Survival
33%
Cisplatin
33%
Irinotecan
33%
Predictors of Progression
33%
Metastatic Pancreatic Ductal Adenocarcinoma
33%
Xeloda
33%
Diagnostic Tool
16%
Clinical Management
16%
KRAS mutation
16%
Predictive Value
16%
Clinical Outcomes
16%
Johns Hopkins University
16%
Long Progression-free Survival
16%
Chemotherapy Regimen
16%
Biomarker Testing
16%
Clinical Decision-making
16%
TP53 mutation
16%
Image Evaluation
16%
Treatment Strategy
16%
Capecitabine
16%
Early Progression
16%
Concordance Index
16%
Nine-level
16%
Rapid Development
16%
Metastatic Pancreatic Cancer
16%
Change in Treatment
16%
Resistance Development
16%
Protein Biomarkers
16%
Biomarkers of Response
16%
DNA Assay
16%
Traditional Biomarkers
16%
TP53 Variants
16%
Metronomic Chemotherapy
16%
Protein Imaging
16%
Tumor-agnostic
16%
Medicine and Dentistry
Chemotherapy Agent
100%
Pancreas Adenocarcinoma
100%
Cell-Free DNA
100%
Biological Marker
66%
Gene Frequency
66%
Progression Free Survival
66%
Gemcitabine
50%
Paclitaxel
50%
Capecitabine
50%
Carcinoembryonic Antigen
50%
CA19-9
50%
Cisplatin
33%
Overall Survival
33%
Irinotecan
33%
Diagnosis
16%
Neoplasm
16%
Pancreas Cancer
16%
Chemotherapy Regimens
16%
Clinical Management
16%
Clinical Decision Making
16%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Progression Free Survival
100%
Pancreas Adenocarcinoma
100%
Chemotherapy Agent
100%
Paclitaxel
75%
Gemcitabine
75%
Carcinoembryonic Antigen
75%
Capecitabine
75%
Cisplatin
50%
Irinotecan
50%
Overall Survival
50%
Neoplasm
25%
Pancreas Cancer
25%
Chemotherapy Regimens
25%